Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0809 • ACR Convergence 2023
Underserved by Rehabilitation: Characteristics Among Adults with Rheumatoid Arthritis
Chris Lane¹, Lauren Mihalek², Kelli Allen³, Beth Jonas⁴, Patti Katz⁵ and Louise Thoma⁶, ¹UNC Chapel Hill, Chapel Hill, NC, ²University of North Carolina - Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Durham, NC, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵University of California San Francisco, San Rafael, CA, ⁶University of North Carolina, Chapel Hill, NC
Background/Purpose: Adults with rheumatoid arthritis (RA) often experience functional limitations (e.g., difficulty walking, dressing oneself), even with low disease activity and good pharmaceutical management. Rehabilitation…
Abstract Number: 0980 • ACR Convergence 2023
Temporal Trends in Incidence Rates of Seropositive and Seronegative Rheumatoid Arthritis: A Danish Nationwide Population-based Study
Bolette Soussi¹, René Cordtz², Kirsten Duch², Salome Kristensen³, Asta Linauskas⁴, Christian Bork⁵, Erik Schmidt⁶ and Lene Dreyer³, ¹Center of Rheumatic Research Aalborg, Department of Rheumatology, and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark, ²Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ³Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁴Department of Rheumatology, North Denmark Region Hospital, and Department of Clinical Medicine, Aalborg University, Hjørring, Denmark, ⁵Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark, ⁶Department of Medicine and Cardiology, Viborg Regional Hospital, and Department of Clinical Medicine, Aalborg University, Viborg, Aalborg, Denmark
Background/Purpose: With growing availability of autoantibody testing and autoantibodies gaining more weight in the 2010 ACR/EULAR classification criteria of rheumatoid arthritis (RA), an increasing incidence…
Abstract Number: 1031 • ACR Convergence 2023
Geographic Socioeconomic Influences on Disease Activity in Rheumatoid Arthritis in an Academic and Safety-Net Hospital System
Joseph Kim¹, Song Zhang² and Elizabeth Blair Solow¹, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased morbidity and mortality, particularly if RA is poorly controlled. The effects of socioeconomic deprivation have not been…
Abstract Number: 1261 • ACR Convergence 2023
Network Analysis of Depression and Anxiety Symptoms in Chinese Rheumatoid Arthritis Patients
Zhang Lijuan and Wu Beiwen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Rheumatoid arthritis (RA) patients are susceptible to comorbid anxiety and depression. From the network model perspective, comorbidity is due to direct interactions between depression…
Abstract Number: 1279 • ACR Convergence 2023
What Is the Nature of Functional Problems in People with Rheumatoid Arthritis and Severe Disability; An Analysis Using the International Classification of Functioning, Disability and Health as a Reference
Max Teuwen¹, Salima van Weely¹, Thea Vliet Vlieland², Thom Douw³, Manja van Wissen¹, Alfons den Broeder⁴, Dirkjan van Schaardenburg⁵, Cornelia van den Ende⁴ and Maaike gademan¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leids University Medical Center, Leiden, Netherlands, ³Leiden University of Applied Sciences, Leiden, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: There is a lack of knowledge about the limitations in activities and participation experienced by a subgroup of people with rheumatoid arthritis (RA) and…
Abstract Number: 1295 • ACR Convergence 2023
Having More Tender Than Swollen Joints Is Associated with Worse Functional Outcomes in Patients with Early RA in a Prospective Real-World Cohort
Charis Meng¹, Yvonne Lee², Orit Schieir³, Marie-France Valois⁴, Margaret Butler¹, Gilles Boire⁵, Glen Hazelwood⁶, Carol Hitchon⁷, Edward Keystone⁸, Diane Tin⁹, Carter Thorne¹⁰, Louis Bessette¹¹, Janet Pope¹², Susan Bartlett¹³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University, Chicago, IL, ³McGill University, Montréal, QC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Manitoba, MB, Canada, ⁸Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁹Centre of Arthritis Excellence, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ¹²University of Western Ontario, London, ON, Canada, ¹³McGill University, Montreal, QC, Canada
Background/Purpose: Early RA patients may present with more tender than swollen joints, which can persist during DMARD therapy. Elevated TSJD (tender-swollen joint difference) is often…
Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
Abstract Number: 1328 • ACR Convergence 2023
Switching Biologics or Janus Kinase Inhibitors Is Effective in Difficult-to-treat Rheumatoid Arthritis, Regardless of Inflammation
Katsuaki Onishi¹, Yutaro Yamada², Tadashi Okano², Kenji Mamoto², Shohei Anno³, Tatsuya Koike⁴ and Hiroaki Nakamura², ¹Baba Memorial Hospital, Osaka, Japan, ²Osaka Metropolitan University, Osaka, Japan, ³Yodogawa Christian Hospital, Osaka, Japan, ⁴Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: Although biologics (BIO) or Janus kinase inhibitors (JAKi) have improved treatment for rheumatoid arthritis (RA), there are patients with difficult disease activity control even…
Abstract Number: 1344 • ACR Convergence 2023
Efficacy and Safety of JAK Inhibitors in Difficult to Treat Rheumatoid Arthritis in Clinical Practice
Omar AL TABAA¹, Sophie HECQUET², Marion THOMAS³, Sandrine CARVES¹, Alice Combier¹, Corinne MICELI⁴, Olivier Fogel³, Anna Molto³, Yannick ALLANORE⁵ and Jerome AVOUAC⁶, ¹APHP / Cochin Hospital, Paris, France, ²APHP / Cochin Hospital / Paris University, Paris, France, ³HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁴Université de Paris Cité, HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ⁵Université Paris Cité, Paris, France, ⁶Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Use of JAK inhibitors (JAKi) may be challenged in difficult to treat rheumatoid arthritis (D2TRA) by the multiplicity of previous treatment lines and the…
Abstract Number: 1659 • ACR Convergence 2023
Cellular Deconstruction of Stromal and Myeloid Cell Compartments in the Inflamed Synovium of Juvenile Idiopathic Arthritis
Christopher Mahony¹, Chrissy Bolton², Charlotte Smith¹, Vicky Alexiou³, Huong Nguyen³, Patricia Reis-Nisa¹, Søren Lomholt⁴, Annie Hackland¹, Sunit Davda⁵, Sugrah Sultan⁶, Charlene Foley⁵, Catherine Cotter⁶, Klaudia Kupiec³, Calliope Dendrou², Elizabeth C Rosser⁷, Accelerating Medicines Partnership (AMP): RA/SLE⁸, Fan Zhang⁹, Soumya Raychaudhuri⁸, Michael Brenner¹⁰, Christopher Buckley², Manigandan Thyagarajan⁶, Accelerating Medicines Partnership Program RA SLE Network¹¹, Zishan Shiekh⁶, Sandrine Compeyrot-Lacassagne⁵, Samantha Chippington⁵, Mark Coles², Eslam Al-Abadi⁶, Andrew Filer¹, Tissue Research in Childhood Onset Inflammatory Arthritis (TRICIA) Consortium¹², Lucy R Wedderburn³ and Adam Croft¹, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³UCL Great Ormond Street Institute of Child Health, London, United Kingdom, ⁴Aarhus University, Aarhus, Denmark, ⁵Great Ormond Street Hospital, London, United Kingdom, ⁶Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, ⁷University College London, London, United Kingdom, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Colorado, Aurora, CO, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²MRC, Birmingham, United Kingdom
Background/Purpose: The synovial membrane is the primary target tissue during the effector phase of inflammatory arthritis in children and young people with Juvenile Idiopathic Arthritis…
Abstract Number: 1729 • ACR Convergence 2023
An Antibody-drug Conjugate of Anti-TNFα Antibody and a Novel Glucocorticoid Molecule Exerts Synergistic Anti-inflammatory Effects for Treatment of Autoimmune Diseases
Yuhao Qin¹, Wenming Ren², Liangqin Tong³, lu su³ and cheng liao³, ¹Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China, ²Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pudong New District, China, ³Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China
Background/Purpose: Tumor necrosis factor α (TNFα) is a pivotal pro-inflammatory cytokine. And TNF inhibitors are the most successful anti-rheumatic drugs for the treatment of autoimmune…
Abstract Number: 1745 • ACR Convergence 2023
Chronic Inflammation and Collagen IV Fragment Canstatin Influence Rheumatoid Arthritis Synovial Fibroblast and Endothelial Cell Interactions in Vitro and in Vivo
Corinna Heck¹, Sophie Haun¹, Daria Kürsammer¹, Klaus Frommer¹, Mona Arnold¹, Markus Rickert², Katrin Susanne Lips³, Stefan Rehart⁴, Ulf Müller-Ladner¹ and Elena Neumann¹, ¹Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ²Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, ³Justus Liebig University Gießen, Department of Experimental Trauma Surgery, Giessen, Germany, ⁴Dept. of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital Frankfurt, Frankfurt, Germany
Background/Purpose: In the inflamed synovium of RA patients, increased and altered angiogenesis is a pathological feature. Key players are chronically activated RA synovial fibroblasts (RASF),…
Abstract Number: 1761 • ACR Convergence 2023
JAK/STAT Inhibition Modifies the Innate Lymphoid Cells 1 Immune Response in Patients with Rheumatoid Arthritis
Lidia La Barbera¹, Marianna Lo Pizzo¹, Chiara Rizzo¹, Leila Mohammadnezhad¹, federica Camarda¹, Francesco Ciccia² and Giuliana Guggino¹, ¹University of Palermo, Palermo, Italy, ²University of Campania - Luigi Vanvitelli, Naples, Italy
Background/Purpose: Recent evidence suggests that innate lymphoid cells (ILCs) might be involved in rheumatoid arthritis (RA) pathogenesis and individuals at risk of RA exhibited an…
Abstract Number: 1821 • ACR Convergence 2023
The “Weekend Effect” and Rheumatological Association in Patients with Diffuse Alveolar Haemorrhage
Shobhit Piplani¹, Shreya Gulati², Vladimir Jelic¹, Asad Ahmed³, Sung Mi Yoon¹, Donclair Brown¹, Miroslav Radulovic¹ and Beverly Johnson⁴, ¹Jacobi Medical Center/North Central Bronx, Albert Einstein College of Medicine, NYC Health and Hospitals, Bronx, NY, ²Jawahar lal Nehru Medical College, New York, NY, ³SUNY Downstate, Brooklyn, NY, ⁴Albert Einstein College of Medicine, Jacobi/NCB, New York, NY
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication commonly associated with autoimmune disorders. Limited treatment options are available for DAH, and time to…
Abstract Number: 1906 • ACR Convergence 2023
Implementation Practices for the 2022 American College of Rheumatology Guidelines for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis
Laura Nichols¹, Meghan Scheibe², Ellen Erie³, Austin Nickell³ and Abe Sahmoun³, ¹Sanford Health, Fargo, ND, ²Sanford Health, West Fargo, ND, ³University of North Dakota, Fargo, ND
Background/Purpose: In November 2022, the American College of Rheumatology (ACR) released the ACR Guidelines for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].